Fig. 4: The IRE1α–XBP1s pathway is crucial for drug resistance and HCC malignancy. | Cell Death Discovery

Fig. 4: The IRE1α–XBP1s pathway is crucial for drug resistance and HCC malignancy.

From: RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway

Fig. 4

A Representative flow cytometry analysis of Annexin V-PI staining in sorafenib-resistant Huh7 cells with or without RCN1 silencing, in the presence of 5 μM sorafenib. B Representative flow cytometry analysis of Annexin V-PI staining in sorafenib-resistant Huh7 cells in the presence of 5 μM sorafenib and different doses of MKC8866. C Cell proliferation in sorafenib-resistant Huh7 cells with IRE1a knockdown assessed using an EdU assay. D Transwell assays of cell migration and invasion in sorafenib-resistant Huh7 cells after IRE1α knockdown. E Cell proliferation in sorafenib-resistant Huh7 cells assessed using EdU assays after treatment with 0.3 μM MKC8866. F Transwell assays of cell migration and invasion in sorafenib-resistant Huh7 cells in the presence of 0.3 μM MKC8866. Data are presented as the means ± SEM of three independent experiments. ns not significantly different. **P < 0.01; ***P < 0.001; ****P < 0.0001, t-test.

Back to article page